BrainChild Bio, Inc.
PrivateLast Round
Series A
Sep 8, 2026
Total Funding Raised
$116.3M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
BrainChild Bio, Inc. is a biotechnology company that develops CAR T-cell therapies for the treatment of pediatric and adult central nervous system tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BrainChild Bio, Inc. Comparables
Compare BrainChild Bio, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cellevolve Bio | 83% | |
| GlioCART GmbH | 79% | |
| Chimeric Therapeutics Limited | 77% |
BrainChild Bio, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 8, 2026 | ||||
| Grant | Jan 21, 2025 | ||||
| Seed | Dec 5, 2023 |
Key People
Founding team and executive leadership
BrainChild Bio, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Washington Research Foundation Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 8, 2026
$116M round with participation from Seattle Children's Research Institute.
- Apr 17, 2026
Monthly visitors increased 85% MoM.
Recent news
Latest coverage and updates
- expands_offices_toSep 21, 2026
BrainChild Bio, Inc. expanded offices to Seattle, Washington, United States, Northern America, Americas on Sep 21st '26.
- receives_financingSep 8, 2026
BrainChild Bio, Inc. received financing of $100M in Series A on Jul 1st '23.
- is_developingSep 8, 2026
BrainChild Bio, Inc. is developing CAR T cell therapies to treat tumors in the central nervous system on Sep 8th '26.
- receives_financingSep 8, 2026
BrainChild Bio, Inc. received financing of $116M in Series A on Sep 8th '26.
- is_developingSep 8, 2026
BrainChild Bio, Inc. is developing CAR T therapeutics for brain cancer on Sep 1st '26.
BrainChild Bio, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about BrainChild Bio, Inc.'s valuation, stock price, and market status.
Is BrainChild Bio, Inc. a public or private company?
BrainChild Bio, Inc. is a private company.
What is the current stock price of BrainChild Bio, Inc.?
BrainChild Bio, Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is BrainChild Bio, Inc. worth (valuation)?
Valuation information for BrainChild Bio, Inc. is not publicly available.
Can I buy BrainChild Bio, Inc. stock?
BrainChild Bio, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was BrainChild Bio, Inc.'s last funding round?
BrainChild Bio, Inc.'s most recent funding round was Grant on January 21, 2025.
Who are the main investors in BrainChild Bio, Inc.?
Investor information for BrainChild Bio, Inc. is not publicly disclosed.
Will BrainChild Bio, Inc. IPO soon?
No public IPO plans have been announced for BrainChild Bio, Inc..
How can I track BrainChild Bio, Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor BrainChild Bio, Inc.'s secondary market activity and sign up for updates.